PhIII bust forces Ultragenyx to scrap drug for rare muscle disease
Analysts had been speculating that a success in Ultragenyx’s Phase III study of Ace-ER for rare cases of GNE myopathy could trigger some near-term regulatory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
